Johnson & Johnson (JNJ)
Largest Insider Buys in Sector
JNJ Stock Price History Chart
JNJ Stock Performance
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; …
Insider Activity of Johnson & Johnson
Over the last 12 months, insiders at Johnson & Johnson have bought $147,220 and sold $11.65M worth of Johnson & Johnson stock.
On average, over the past 5 years, insiders at Johnson & Johnson have bought $137,453 and sold $36.8M worth of stock each year.
Highest buying activity among insiders over the last 12 months: WEINBERGER MARK A (director) — $147,220.
The last purchase of 1,000 shares for transaction amount of $147,220 was made by WEINBERGER MARK A (director) on 2024‑12‑12.
List of Insider Buy and Sell Transactions, Johnson & Johnson
| 2024-12-12 | director | 1,000 <0.0001% | $147.22 | $147,220 | -0.55% | |||
| 2024-08-30 | Sale | VP Corporate Controller | 5,635 0.0002% | $165.06 | $930,113 | -3.48% | ||
| 2024-03-13 | Sale | EVP, Global Corp Affairs | 8,891 0.0004% | $162.16 | $1.44M | -3.91% | ||
| 2024-02-09 | Sale | EVP, WW Chair, Pharmaceuticals | 59,397 0.0024% | $156.27 | $9.28M | -0.64% | ||
| 2023-07-26 | Sale | See Remarks | 14,698 0.0006% | $172.00 | $2.53M | -9.68% | ||
| 2023-07-25 | Sale | Exec VP, Chief HR Officer | 20,000 0.0008% | $170.32 | $3.41M | -9.45% | ||
| 2023-06-12 | Sale | EVP, Chief TO and Risk Officer | 12,465 0.0005% | $160.00 | $1.99M | -1.34% | ||
| 2023-03-06 | Sale | See Remarks | 1,061.68 <0.0001% | $154.66 | $164,199 | +3.00% | ||
| 2022-12-13 | Sale | Exec VP, CFO | 14,781 0.0006% | $179.60 | $2.65M | -9.46% | ||
| 2022-11-30 | Sale | EVP, WW Chair, MedTech | 73,323 0.0027% | $175.47 | $12.87M | -8.48% | ||
| 2022-11-22 | Sale | EVP, WW Chair, Pharmaceuticals | 76,923 0.0029% | $176.78 | $13.6M | -7.60% | ||
| 2022-11-18 | Sale | Controller, CAO | 16,928 0.0006% | $175.00 | $2.96M | -6.62% | ||
| 2022-11-09 | Sale | EVP, Chief GSC Officer | 16,410 0.0006% | $173.42 | $2.85M | -4.34% | ||
| 2022-11-04 | Sale | Exec VP, WW Chair, Consumer | 35,246 0.0013% | $171.18 | $6.03M | -3.71% | ||
| 2022-10-24 | Sale | Exec VP, Chief HR Officer | 9,064 0.0003% | $171.36 | $1.55M | -2.95% | ||
| 2022-10-24 | Sale | Exec VP, Chief HR Officer | 78,458 0.003% | $171.25 | $13.44M | -2.95% | ||
| 2022-10-24 | Sale | See Remarks | 15,000 0.0006% | $171.55 | $2.57M | -2.95% | ||
| 2022-10-19 | Sale | Exec VP, Chief HR Officer | 92,990 0.0035% | $164.50 | $15.3M | +0.97% | ||
| 2022-10-19 | Sale | Exec VP, Chief HR Officer | 67,591 0.0026% | $164.50 | $11.12M | +0.97% | ||
| 2022-06-10 | Sale | EVP, Chief GSC Officer | 73,126 0.0028% | $173.00 | $12.65M | -2.88% |
Insider Historical Profitability
| WEINBERGER MARK A | director | 1000 0% | $144.47 | 1 | 0 | |
| PRINCE CHARLES | director | 28520 0.0012% | $144.47 | 6 | 0 | +5.17% |
| PEREZ WILLIAM D | director | 16030 0.0007% | $144.47 | 14 | 0 | +2.64% |
| MULCAHY ANNE M | director | 6537 0.0003% | $144.47 | 1 | 0 | +1.82% |
| Joly Hubert | director | 5000 0.0002% | $144.47 | 1 | 0 | +5.24% |
Institutional Investor Ownership
| The Vanguard Group | $36.22B | 9.51 | 228.94M | -0.2% | -$71.05M | 0.67 | |
| BlackRock | $30.01B | 7.88 | 189.73M | +1.83% | +$540.76M | 0.65 | |
| State Street | $21.12B | 5.55 | 133.52M | +0.46% | +$97.36M | 0.86 | |
| Geode Capital Management | $8.42B | 2.22 | 53.32M | +4.03% | +$326.07M | 0.72 | |
| Morgan Stanley | $6.73B | 1.77 | 42.55M | +2.14% | +$140.86M | 0.5 |